Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Consensus Price Target of $15.86 According to Brokerages

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has been given an average rating of “Buy” by the ten analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $15.86.

Several research analysts recently commented on IVA shares. Cantor Fitzgerald began coverage on shares of Inventiva in a report on Friday, July 17th. They issued an “overweight” rating on the stock. Weiss Ratings upgraded Inventiva from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 23rd. Guggenheim boosted their price target on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Truist Financial lifted their target price on Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. Finally, Wall Street Zen raised Inventiva from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd.

Institutional Trading of Inventiva

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Platt Investment Counsel LLC bought a new position in Inventiva in the third quarter worth approximately $45,000. China Universal Asset Management Co. Ltd. grew its holdings in Inventiva by 78.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company’s stock worth $142,000 after buying an additional 17,000 shares in the last quarter. Engineers Gate Manager LP raised its position in Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after buying an additional 43,280 shares during the last quarter. Finally, Seven Fleet Capital Management LP purchased a new stake in Inventiva in the 1st quarter valued at $1,111,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Stock Performance

Shares of Inventiva stock opened at $3.65 on Monday. Inventiva has a 1 year low of $2.82 and a 1 year high of $7.29. The business has a 50 day moving average price of $3.82 and a 200 day moving average price of $4.89.

Inventiva (NASDAQ:IVA) last released its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The business had revenue of $0.75 million for the quarter. On average, analysts anticipate that Inventiva will post -0.79 EPS for the current year.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.